Pembrolizumab has robust, durable clinical benefit in patients with heavily pretreated CCGC and was tolerated in the overall population,” researchers wrote.

Two new measures tied to outcomes drawn from data in the CLEAR phase 3 trial will be presented during the ASCO Genitourinary ...

Endometrial cancer (EC) is the most common gynecological malignancy in developed countries, with its incidence steadily rising worldwide due to increasing ...

Cervical cancer is one of the most preventable cancers, yet it remains a significant health threat. Here’s why prevention is ...

Completion of SON-1010 (IL12-FHAB) monotherapy dose escalation in Phase 1 SB101 trial; Stable disease (SD) at four months post-initiation of ...

Immunotherapeutics have transformed cancer outcomes. It is crucial that response patterns seen with them are assessed ...

This all started at the annual BSP reception for the banking community last month when Philippine Stock Exchange chairman Jose “Titoy” Pardo and Monetary Board member Romeo Bernardo, along with a few ...

Emma-Louise Lucas, a mother of one from Manchester, at just 31 received the shocking news that she had a rare type of cancer ...

Results from the PEACOCC trial warrant further investigation into treatment with pembrolizumab in patients with previously ...

Welcome to the Merck & Company Q4 sales and earnings conference call. [Operator instructions] This call is being recorded. [Operator instructions] I would now like to turn the call over to Mr. Peter ...